Predicting treatment response in multicenter non|small cell lung ...

Predicting treatment response in multicenter non-small cell lung ...

A multicenter treatment response prediction model is designed by FL for predicting the probability of remission of NSCLC patients.

Predicting treatment response in multicenter non-small cell lung ...

We demonstrate that the performance of a FL predictive model, developed by combining convolutional neural networks (CNNs) with data from ...

Predicting treatment response in multicenter non-small cell lung ...

Multicenter non-small cell lung cancer (NSCLC) patient data is information-rich. However, its direct integration becomes exceptionally challenging due to ...

(PDF) Predicting treatment response in multicenter non-small cell ...

This approach enables the utilization of multicenter data with maximum benefit while ensuring privacy safeguards. Based on pre-radiotherapy planning target ...

Predicting treatment response in multicenter non-small cell lung ...

Predicting treatment response in multicenter non-small cell lung cancer patients based on federated learning · Yuan Liu, Jinzao Huang, +3 authors. Jianfeng Qiu ...

Predicting treatment response in multicenter non-small cell lung ...

Background: Multicenter non-small cell lung cancer (NSCLC) patient data is information-rich. However, its direct integration becomes exceptionally ...

Predicting response to immunotherapy in advanced non-small-cell ...

Lung cancer is the leading cause of cancer-related mortality worldwide.1 Immune checkpoint inhibitors (ICIs), which target programmed cell death protein 1 (PD-1) ...

Predicting chemotherapy response in non-small-cell lung cancer via ...

This study aims to evaluate the ability of peritumoral, intratumoral, or combined computed tomography (CT) radiomic features to predict ...

Non-invasive multimodal CT deep learning biomarker to predict ...

Objectives Although neoadjuvant immunochemotherapy has been widely applied in non-small cell lung cancer (NSCLC), predicting treatment response remains a ...

Predicting response to immunotherapy in non-small cell lung cancer

Baseline clinical and CT data for 117 aNSCLC patients treated with nivolumab were correlated with overall survival (OS). Models for predicting treatment ...

Predicting treatment response in multicenter non-small cell lung ...

Abstract Background Multicenter non-small cell lung cancer (NSCLC) patient data is information-rich. However, its direct integration becomes exceptionally ...

Deep learning for predicting major pathological response to ...

For early and locally advanced non-small cell lung cancer (NSCLC), a surgical resection continues to the mainstay of curative-intent therapeutic ...

ctDNA response after pembrolizumab in non-small cell lung cancer

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ...

A multicenter international randomized phase III study comparing ...

Irinotecan dose–response relationships in non-small cell lung ... Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a ...

Machine learning models based on radiomics features to predict ...

... predict treatment response, biomarker status, and ... Recommended Articles. Lung Cancer—Non-Small Cell Metastatic May 31, 2023. Predicting ...

Treatment patterns and clinical outcomes of patients with resectable ...

Neoadjuvant immunotherapy has ushered in a new era of perioperative treatment for resectable non–small cell lung cancer (NSCLC). However, large-scale data ...

Effectiveness of first-line anticancer treatment may predict treatment ...

... multicenter retrospective CLARITY study. Lung ... predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients.

Epigenetic prediction of response to anti-PD-1 treatment in non ...

Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung cancer (NSCLC) has improved the survival of patients.

Radiotherapy for non-small cell lung cancer in the immunotherapy era

Although ICIs revolutionized the treatment of NSCLC, only 20% of unselected patients with advanced disease respond to PD-1/PD-L1 inhibitors, and 45% of selected ...

Predictive value of PERCIST for locally NSCLC - Dove Medical Press

Predictive Value of PERCIST for Locally Advanced Non-Small Cell Lung Cancer Treated with Preoperative Induction Therapy – A Multicenter Study in ...